These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23289685)

  • 1. Prudent precaution in clinical trials of nanomedicines.
    Marchant GE; Lindor RA
    J Law Med Ethics; 2012; 40(4):831-40. PubMed ID: 23289685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond human subjects: risk, ethics, and clinical development of nanomedicines.
    Kimmelman J
    J Law Med Ethics; 2012; 40(4):841-7. PubMed ID: 23289686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsible conduct in nanomedicine research: environmental concerns beyond the common rule.
    Resnik DB
    J Law Med Ethics; 2012; 40(4):848-55. PubMed ID: 23289687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical issues in clinical trials involving nanomedicine.
    Resnik DB; Tinkle SS
    Contemp Clin Trials; 2007 Jul; 28(4):433-41. PubMed ID: 17166777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is unique about nanomedicine? The significance of the mesoscale.
    Khushf G; Siegel RA
    J Law Med Ethics; 2012; 40(4):780-94. PubMed ID: 23289680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concepts of risk in nanomedicine research.
    Hogle LF
    J Law Med Ethics; 2012; 40(4):809-22. PubMed ID: 23289683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethics in nanomedicine.
    Resnik DB; Tinkle SS
    Nanomedicine (Lond); 2007 Jun; 2(3):345-50. PubMed ID: 17716179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Handling worker and third-party exposures to nanotherapeutics during clinical trials.
    Ramachandran G; Howard J; Maynard A; Philbert M
    J Law Med Ethics; 2012; 40(4):856-64. PubMed ID: 23289688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building an ethical foundation for first-in-human nanotrials.
    Dresser R
    J Law Med Ethics; 2012; 40(4):802-8. PubMed ID: 23289682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precautionary discourse. Thinking through the distinction between the precautionary principle and the precautionary approach in theory and practice.
    Dinneen N
    Politics Life Sci; 2013; 32(1):2-21. PubMed ID: 24047088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A portrait of nanomedicine and its bioethical implications.
    Hall RM; Sun T; Ferrari M
    J Law Med Ethics; 2012; 40(4):763-79. PubMed ID: 23289679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does the precautionary principle mean for evidence-based dentistry?
    Tickner J; Coffin M
    J Evid Based Dent Pract; 2006 Mar; 6(1):6-15. PubMed ID: 17138389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making clinical trials safer for human subjects.
    Baram M
    Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
    [No Abstract]   [Full Text] [Related]  

  • 16. Beyond biotechnology: FDA regulation of nanomedicine.
    Miller J
    Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment.
    Wolf SM
    J Law Med Ethics; 2012; 40(4):712-5. PubMed ID: 23289676
    [No Abstract]   [Full Text] [Related]  

  • 18. The precautionary principle and the regulation of U.S. food and drug safety.
    Soule E
    J Med Philos; 2004 Jun; 29(3):333-50. PubMed ID: 15512976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical issues in nanomedicine: Tempest in a teapot?
    Allon I; Ben-Yehudah A; Dekel R; Solbakk JH; Weltring KM; Siegal G
    Med Health Care Philos; 2017 Mar; 20(1):3-11. PubMed ID: 27522374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing environmental risks: the benefits of a place-based approach.
    Loring PA; Duffy LK
    Rural Remote Health; 2011; 11(3):1800. PubMed ID: 21936605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.